Alvotech Soars 20% on Lotus Deal and FDA Progress, but Can a Revenue-Light Biosimilar Maker Justify the Momentum?

Shares of Alvotech surged 20.3% to ISK 628 on August 24, as investors cheered a one-two punch: a new licensing deal with Taiwan-based Lotus Pharmaceutical and progress clearing regulatory hurdles with the U.S. Food and Drug Administration. The rally—built on roughly 3.16 million shares traded—was company-specific, not a rising-tide market story, and it raises a pointed question: does the pipeline now support the price?

• A $150 Million Deal That Changes How Alvotech Sells in America. The Lotus agreement is worth up to approximately $150 million in upfront and milestone payments, plus ongoing product-supply revenue. Crucially, under a semi-exclusive arrangement, Alvotech retains the right to sell both products directly in the U.S. alongside Lotus's subsidiary Alvogen —a first for the company. The two candidates target cheaper versions of AstraZeneca's cancer drug Imfinzi and Roche's hemophilia treatment Hemlibra. Imfinzi alone generated global sales of roughly $6.1 billion in 2025 , and Hemlibra revenue projections suggested it could reach $4 billion by 2025. Even modest biosimilar penetration of those markets would be material. Alvotech's cancer-drug candidate is the first announced therapeutic biosimilar to Imfinzi in development globally , giving it a potential head start.

• First-Half Numbers Show a Revenue Dip, Not a Collapse. Adjusted revenue fell to $211.9 million from $306.1 million a year earlier , while adjusted EBITDA (a rough measure of cash profits) dropped 12.7% to $46.9 million as a manufacturing improvement program hurt output.

Management maintained full-year 2026 guidance of $650–$700 million in revenue and $180–$220 million in adjusted EBITDA , signaling a steep second-half rebound is expected.

• FDA Clearance Removes a Key Overhang. The FDA closed its May 2026 inspection of Alvotech's Reykjavik plant, classifying it as "Voluntary Action Indicated"—an outcome that means no mandatory corrective action.

The company has resubmitted applications for three biosimilar programs and expects FDA decisions during Q4 2026.

• The Balance Sheet Is Thinning. Cash fell to $142.8 million from $172.4 million at year-end 2025 , though a recent $165 million equity raise and a $75 million loan from GoldenTree Asset Management provide a cushion heading into potential launches. Whether this runway is sufficient depends entirely on how fast revenue recovers and whether the FDA delivers approvals on schedule.